| Literature DB >> 28287686 |
Amornluck Krasaelap, Shailender Madani.
Abstract
Functional gastrointestinal disorders (FGIDs) negatively affect children's quality of life and health care costs. It has been proposed that alteration of gut serotonin leads to gastrointestinal dysmotility, visceral hypersensitivity, altered gastrointestinal secretions, and brain-gut dysfunction. Cyproheptadine, a serotonin antagonist, has been shown to be a potentially effective and safe treatment option in children who meet the clinical criteria for FGIDs. Well-designed multicenter trials with long-term follow-up are needed to further investigate its efficacy. [Pediatr Ann. 2017;46(3):e120-e125.]. Copyright 2017, SLACK Incorporated.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28287686 DOI： 10.3928/19382359-20170213-01
Source DB: PubMed Journal: Pediatr Ann ISSN： 0090-4481 Impact factor: 1.132